Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Paling

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Neurology and Therapy|July 14, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis TreatmentStephen L Hauser, Ludwig Kappos, Amit Bar-Or, et al.
Multiple Sclerosis and Related Disorders|June 3, 2025
Approach to JCV testing with natalizumab biosimilar: a UK consensus statementRuth Dobson, Tarunya Arun, James Varley, et al.
Journal of the Neurological Sciences|March 18, 2022
The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implicationsCarolyn A Young, Roger Mills, Dawn Langdon, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 24, 2022
Measuring coping in multiple sclerosis: The Coping Index-MSCarolyn A Young, Roger J Mills, Dawn Langdon, et al.
The Lancet. Neurology|January 30, 2016
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trialRhian Raftopoulos, Simon J Hickman, Ahmed Toosy, et al.
BMJ Open|February 5, 2024
Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trialGavin Brittain, Jennifer Petrie, Kate E M Duffy, et al.
BMJ Neurology Open|September 12, 2024
Brain reserve and physical disability in secondary progressive multiple sclerosisNevin John, Yingtong Li, Floriana De Angelis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 31, 2026
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)Emma C Tallantyre, Sarah M Planchon, Harriet Howard, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Neurology and Therapy|July 14, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis TreatmentStephen L Hauser, Ludwig Kappos, Amit Bar-Or, et al.
Multiple Sclerosis and Related Disorders|June 3, 2025
Approach to JCV testing with natalizumab biosimilar: a UK consensus statementRuth Dobson, Tarunya Arun, James Varley, et al.
Journal of the Neurological Sciences|March 18, 2022
The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implicationsCarolyn A Young, Roger Mills, Dawn Langdon, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 24, 2022
Measuring coping in multiple sclerosis: The Coping Index-MSCarolyn A Young, Roger J Mills, Dawn Langdon, et al.
The Lancet. Neurology|January 30, 2016
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trialRhian Raftopoulos, Simon J Hickman, Ahmed Toosy, et al.
BMJ Open|February 5, 2024
Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trialGavin Brittain, Jennifer Petrie, Kate E M Duffy, et al.
BMJ Neurology Open|September 12, 2024
Brain reserve and physical disability in secondary progressive multiple sclerosisNevin John, Yingtong Li, Floriana De Angelis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 31, 2026
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)Emma C Tallantyre, Sarah M Planchon, Harriet Howard, et al.
Pageof 4